Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

224.81 +0.46 (+0.21%)

Official Closing Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

94 95 Next >

8 Health Care Stocks Whale Activity In Today's Session ↗

May 01, 2025

Via Benzinga

Netflix, Sherwin-Williams, AbbVie And More On CNBC's 'Final Trades' ↗

April 30, 2025

Via Benzinga

AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis ↗

April 29, 2025

AbbVie wins FDA approval for Rinvoq in giant cell arteritis after strong Phase 3 results and a 57.2% year-over-year sales increase in Q1.

Via Benzinga

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years ↗

April 29, 2025

Via Benzinga

Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next? ↗

April 29, 2025

Shares of AbbVie (ABBV) have gained more than 12% in the past week. But now they are overbought and may reverse.

Via Benzinga

AbbVie's Options Frenzy: What You Need to Know ↗

April 28, 2025

Via Benzinga

US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week ↗

April 29, 2025

U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this...

Via Benzinga

United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect

April 29, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for.

Via StockStory

Topics Government World Trade

Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom ↗

April 28, 2025

Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising...

Via Talk Markets

Topics ETFs Stocks / Equities

Why AbbVie Stock Trounced the Market Today ↗

April 28, 2025

Via The Motley Fool

These S&P500 stocks are moving in today's session ↗

April 28, 2025

Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive...

Via Chartmill

AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst ↗

April 28, 2025

Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments.

Via Benzinga

Exploring the top movers within the S&P500 index during today's session. ↗

April 28, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

3 Dividend Stocks to Buy and Hold for the Next Decade ↗

April 28, 2025

Via The Motley Fool

US Stock Futures Fall As Markets Brace For Earnings From Microsoft, Meta, Apple And Apple This Week: 'Earnings Estimates Don't Signal A Recession' Says Leading Analyst ↗

April 28, 2025

U.S. stock futures are down in early-morning trade on Monday, after ending the previous week on a high note, with back-to-back sessions of strong rallies.

Via Benzinga

Should Investors Be Worried About Dividend King AbbVie? ↗

April 28, 2025

Via The Motley Fool

Topics Earnings Government World Trade

Incyte (INCY) Q1 Earnings Report Preview: What To Look For

April 28, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results tomorrow morning. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence Government World Trade

Regeneron (REGN) Reports Earnings Tomorrow: What To Expect

April 28, 2025

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings tomorrow morning. Here’s what you need to know.

Via StockStory

Topics World Trade

Market Monitor April 28 ( Alphabet, Nvidia & Meta UP, Intel DOWN) ↗

April 28, 2025

US Markets Rise as Big Tech Shines, Trade Tensions Remain a Concern

Via Chartmill

Topics World Trade

AbbVie Stock: Q1 Earnings Beat and EPS Outlook Raised ↗

April 27, 2025

Despite some near-term pressures in aesthetics and legacy products, the overall outlook for 2025 remains positive.

Via Talk Markets

Topics Earnings Stocks / Equities

4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off ↗

April 26, 2025

Via The Motley Fool

Topics Economy Intellectual Property World Trade

How Much Would It Take To Earn $100 A Month From AbbVie Stock ↗

April 25, 2025

Via Benzinga

Why AbbVie Stock Topped the Market Today ↗

April 25, 2025

Via The Motley Fool

Topics Earnings

Wall Street Rally Pauses, Tesla Heads For Strongest Week In 6 Months: What's Driving Markets Friday? ↗

April 25, 2025

Wall Street's three-day rally came to a pause on Friday, with major indices hovering near the flatline by midday in New York as caution returned amid mixed signals on U.S.-China trade relations.

Via Benzinga

AbbVie Raises Profit Outlook But Flags Tariff Risks In Pharma Sector ↗

April 25, 2025

AbbVie stock climbs after Q1 earnings beat and 2025 EPS forecast raise; strong growth in immunology and neuroscience portfolios led the results.

Via Benzinga

Topics Earnings

Get insights into the top movers in the S&P500 index of Friday's pre-market session. ↗

April 25, 2025

Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.

Via Chartmill

AbbVie Reports Upbeat Q1 Earnings, Raises 2025 Earnings Forecast: Retail’s Elated ↗

April 25, 2025

The company’s immunology drugs, Skyrizi and Rinvoq, marked significant revenue growth, offsetting a 50.6% decrease in net revenue from its arthritis drug, Humira.

Via Stocktwits

Topics World Trade

If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy

April 25, 2025

AbbVie is well-positioned for industry-leading growth, as Skyrizi and Rinvoq sales outperform, driving system-wide growth alongside a diversified portfolio.

Via MarketBeat

AbbVie Jumps After Hiking Its Outlook On The Back Of Strong Immunology Sales ↗

April 25, 2025

The company also raised its outlook for 2025, though noted that guidance hike doesn't include potential pharma sector tariffs.

Via Investor's Business Daily

Topics Government World Trade

AbbVie (NYSE:ABBV) Reports Bullish Q1

April 25, 2025

Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 8.4% year on year to $13.34 billion. Its non-GAAP profit of $2.46 per share was 2.6% above...

Via StockStory

Topics Artificial Intelligence

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

94 95 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

AbbVie (NY:ABBV)

All News about AbbVie

Starting at $3.75/week.

Subscribe Today